澳大利亚医保药物遴选的集中审评机制及启示  

Centralized review of medical insurance drugs in Australia and its revelation to Chinese drug review

作　　者：常精华[1] 孙利华[1] 董旻[1] 

机构地区：[1]沈阳药科大学工商管理学院,沈阳110016

出　　处：《中国新药杂志》2008年第17期1465-1467,共3页Chinese Journal of New Drugs

摘　　要：对澳大利亚医保药物集中审评过程的特征及其审评结果和影响进行了分析。审评过程的严谨性、角色的清晰性和数据的透明性对于评价结果的可接受性具有重要的作用。我国应借鉴澳大利亚药品审评的相关经验,寻求保证我国医保药物遴选和新药审评的有效性、透明性和可接受性的途径,以进一步优化我国医保药物遴选和新药审评机制。We analyzed the processes of centralized drug review in Australia, and the outcomes in terms of decisions and impact. Rigor of the process, clarity of roles, and transparency of data and rationale are believed to be important for maximizing the impact and political acceptability of the processes. The drug review in China should get reference from the Australia treatment measures, to ensure more effective, transparent and acceptable in Chinese medical insurance drug selection and drug review.

关 键 词：澳大利亚 医保药物 遴选 集中审评 启示 

分 类 号：R95[医药卫生—药学]